Avila Therapeutics™
Covalent Drugs: Bonding to Targets, Silencing the Disease

Avila Therapeutics will treat human diseases using a remarkably powerful therapeutic approach called ‘protein silencing.’ Using a proprietary platform, Avila generates covalent drugs that strongly and resiliently bond to specific disease-causing proteins, thereby “silencing” them and eradicating the corresponding disease. Avila’s novel covalent drugs have the potential to improve patient outcomes in a fundamentally new way, and Avila is rapidly developing these therapies for a number of diseases, including viral infections, cancers and autoimmune diseases.

5/15/09
Avila Therapeutics Appoints Katrine S. Bosley as Company’s First CEO

4/27/09
xConomy: "Avila Therapeutics May Have Found Achilles Heel of Hepatitis C Virus"

4/25/09
Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting

4/21/09
Avila Presents Data on Novel, Orally-Available, Covalent Drugs Targeting Btk and ErbB Receptors, and Innovative Translation Technology, at Annual AACR Meeting

12/08/08
xConomy: "Avila Comes Out of Stealth to Talk Bonds, Covalent Bonds"